ReviewDiagnostics (Basel, Switzerland)2023
Radiomics Analysis for Multiple Myeloma: A Systematic Review with Radiomics Quality Scoring.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Establishment of a Multimodal Prognostic Prediction Model for Multiple Myeloma Patients Based on Radiomics and Clinical Features: A Retrospective Cohort StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Next-Generation Biomarkers in Multiple Myeloma: Advancing Diagnosis, Risk Stratification, and Precision Therapy Beyond Current Guidelines.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Prediction of ISS and R-ISS Stratification in Newly Diagnosed Multiple Myeloma Using Lumbar Spine MRI Radiomics Model: A Two-Center Multimodal Study.Journal of imaging informatics in medicine · 2026Article
- Revolutionising osseous biopsy: the impact of artificial intelligence in the era of personalized medicine.The British journal of radiology · 2025Review
- Prognostic significance of FDG-PET/CT based radiomics analysis in newly-diagnosed multiple myeloma: a comparative study with clinical assessment.Frontiers in oncology · 2025Article
- Application of radiomics model based on FDG-PET/CT for the assessment of therapeutic effect in patients with newly-diagnosed multiple myeloma.Frontiers in oncology · 2025Article
- Update report on the quality of gliomas radiomics: An integration of bibliometric and radiomics quality score.World journal of radiology · 2024Article
- Role of Imaging in Multiple Myeloma: A Potential Opportunity for Quantitative Imaging and Radiomics?Cancers · 2024Review
- The promise and limitations of artificial intelligence in musculoskeletal imaging.Frontiers in radiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is one of the most common hematological malignancies affecting the bone marrow. Radiomics analysis has been employed in the literature in an attempt to evaluate the bone marrow of MM patients. This manuscript aimed to systematically review radiomics research on MM while employing a radiomics quality score (RQS) to accurately assess research quality in the field. A systematic search was performed on Web of Science, PubMed, and Scopus. The selected manuscripts were evaluated (data extraction and RQS scoring) by three independent readers (R1, R2, and R3) with experience in radiomics analysis. A total of 23 studies with 2682 patients were included, and the median RQS was 10 for R1 (IQR 5.5-12) and R3 (IQR 8.3-12) and 11 (IQR 7.5-12.5) for R2. RQS was not significantly correlated with any of the assessed bibliometric data (impact factor, quartile, year of publication, and imaging modality) (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.